Therapies administered to mothers at risk for preterm birth and neurodevelopmental outcome in their infants

Clinics in Perinatology

Volumn 29, Issue 4, 2002, Pages 725-743

  Ramsey, Patrick S ^a   Rouse, Dwight J ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; BETAMETHASONE; CEFTIZOXIME; CLINDAMYCIN; CORTICOSTEROID; CYTOKINE; DEXAMETHASONE; ERYTHROMYCIN; MAGNESIUM SULFATE; METRONIDAZOLE; MEZLOCILLIN; PHENOBARBITAL; PROTIRELIN; SULTAMICILLIN; UTERUS SPASMOLYTIC AGENT; VITAMIN K GROUP;

BRAIN HEMORRHAGE; BRAIN VENTRICLE DILATATION; CEREBRAL PALSY; CLINICAL TRIAL; ECHOGRAPHY; ENCEPHALOMALACIA; FEMALE GENITAL TRACT INFECTION; HUMAN; INTRAUTERINE INFECTION; LUNG DYSPLASIA; MENTAL DEFICIENCY; NECROTIZING ENTERITIS; NEONATAL RESPIRATORY DISTRESS SYNDROME; NERVOUS SYSTEM DEVELOPMENT; NEUROLOGIC DISEASE; NEUROPROTECTION; NEWBORN CARE; NEWBORN MORBIDITY; NONHUMAN; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VISUAL DISORDER;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; DEVELOPMENTAL DISABILITIES; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; FETAL GROWTH RETARDATION; FETAL MONITORING; HUMANS; INFANT MORTALITY; INFANT, NEWBORN; INTENSIVE CARE, NEONATAL; OBSTETRIC LABOR, PREMATURE; PHENOBARBITAL; PREGNANCY; PREGNANCY OUTCOME; PRENATAL CARE; PREVALENCE; PROGNOSIS; RISK FACTORS; STEROIDS; TOCOLYSIS; TREATMENT OUTCOME; VITAMIN K;

EID: 0036950297     PISSN: 00955108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0095-5108(02)00052-0     Document Type: Review

References (92)

1. Goldenberg RL, Rouse DJ. Prevention of premature birth. N Engl J Med 1998;339:313-20.
2. Creasy RK. Preterm birth prevention: Where are we? Am J Obstet Gynecol 1993;168:1223-30.
3. Allen MC, Donohue PK, Dusman AE. The limit of viability-neonatal outcome of infants born at 22 to 25 weeks' gestation. N Engl J Med 1993;329:1597-601.
4. McCormick MC. The contribution of low birth weight to infant mortality and childhood morbidity. N Engl J Med 1985;312:82.
5. Copper RL, Goldenberg RL, Creasy RK, et al. A multicenter study of preterm birth weight and gestational age-specific neonatal mortality. Am J Obstet Gynecol 1993;168:78-84.
6. Gilstrap III LC, Hauth JC, Bell RE, et al. Survival and short-term morbidity of the premature neonate. Obstet Gynecol 1985;65:37-41.
7. Stevenson DK, Wright LL, Lemons JA, et al. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1993 through December 1994. Am J Obstet Gynecol 1998;179:1632-9.
8. Hack M, Fanaroff AA. Outcomes of extremely immature infants-a perinatal dilemma. N Engl J Med 1993;329:1649-50.
9. Hack M, Fanaroff AA. Outcomes of children of extremely low birthweight and gestational age in the 1990's. Early Hum Dev 1999;53:193-218.
10. Robertson PA, Sniderman SH, Laros Jr RK, et al. Neonatal morbidity according to gestational age and birth weight from five tertiary care centers in the United States, 1983 through 1986. Am J Obstet Gynecol 1992;166:1629-41.
11. Dammann O, Leviton A. Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. Ped Res 1996;42:1-8.
12. Ellenberg J, Nelson K. Birth weight and gestational age in children with cerebral palsy or seizure disorders. Am J Dis Child 1979;133:1044-8.
13. Nelson KB, Ellenberg JH. Antecedents of cerebral palsy. Multivariate analysis of risk. N Engl J Med 1986;315:81-6.
14. Torfs CP, van den Berg B, Oechsli FW, et al. Prenatal and perinatal factors in the etiology of cerebral palsy. J Pediatr 1990;116:615-9.
15. Leviton A, Paneth N. White matter damage in preterm newboms - An epidemiologic perspective. Early Hum Dev 1990;24:1-22.
16. Yoon BH, Romero R, Kim CJ, et al. High expression of tumor necrosis factor-alpha and interleukin-6 in periventricular leukomalacia. Am J Obstet Gynecol 1997;177:406-11.
17. Hack M, Taylor HG, Klein N, et al. School-age outcomes in children with birth weights under 750 g. N Engl J Med 1994;331:753-9.
18. Vohr BR, Wright LL, Dusick AM, et al. Neurodevelopmental and functional outcomes of extremely low birth weight infants in the National Institute of Child Health and Human Development Neonatal Research Network, 1993-1994. Pediatrics 2000;105:1216-26.
19. Alberman E, Stanley F. Guidelines to the epidemiological approach. In: Stanley F, Alberman E, editors. Clinics in Developmental Medicine No. 87: The Epidemiology of the Cerebral Palsies. Lavenham (UK): Lavenham Press Ltd.; 1984. p. 27-31.
20. Aziz K, Vickar DB, Sauve RS, et al. Province-based study of neurologic disability of children weighing 500 through 1249 grams at birth in relation to neonatal cerebral ultrasound findings. Pediatrics 1995;95:837-44.
21. Pinto-Martin JA, Riolo S, Cnaan A, et al. Cranial ultrasound prediction of disabling and non-disabling cerebral palsy at age two in a low birth weight population. Pediatrics 1995;95:249-54.
22. Murphy DJ, Sellers S, MacKenzie IZ, et al. Case-control study of antenatal and intrapartum risk factors for cerebral palsy in very preterm singleton babies. Lancet 1995;346:1449-54.
23. Murphy DJ, Hope PL, Johnson A. Neonatal risk factors for cerebral palsy in very preterm babies: Case-control study. BMJ 1997;314:404-8.
24. Perlman JM. White matter injury in the preterm infant: An important determinant of abnormal neurodevelopmental outcome. Early Hum Dev 1998;53:99-120.
25. Dammann O, Leviton A. The role of perinatal brain damage in developmental disabilities: An epidemiologic perspective. Ment Ret Dev Dis Res Rev 1997;3:13-21.
26. Roth SC, Baudin J, McCormick DC, et al. Relation between ultrasound appearance of the brain of very preterm infants and neurodevelopmental impairment at eight years. Dev Med Child Neurol 1993;35:755-68.
27. Hillier SL, Martius J, Krohn MA, et al. A case-controlled study of chorioamnionic infection and histologic chorioamnionitis in prematurity. N Engl J Med 1988;319:972-8.
28. Andrews WW, Goldenberg RL, Hauth JC. Preterm labor: Emerging role of genital tract infections. Infect Agents Dis 1995;4:196-211.
29. Goldenberg RL, Hauth JC, Andrews WW. Intrauterine infection and preterm delivery. N Engl J Med 2000;342:1500-7.
30. Gibbs RS, Romero R, Hillier SI, et al. A review of premature birth and subclinical infection. Am J Obstet Gynecol 1992;166:1515-28.
31. Asrat T. Intra-amniotic infection in patients with preterm prelabor rupture of membranes. Pathophysiology, detection, and management. Clin Perinatol 2001;28:735-51.
32. Garite TJ, Freeman RK. Chorioamnionitis in the preterm gestation. Obstet Gynecol 1982;59: 539-45.
33. Yoon BH, Jun JK, Romero R, et al. Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha), neonatal brain white matter lesions, and cerebral palsy. Am J Obstet Gynecol 1997;177:19-26.
34. Yoon BH, Romero R, Yang SH, et al. Interleukin-6 concentrations in umbilical cord plasma are elevated in neonates with white matter lesions associated with periventricular leukomalacia. Am J Obstet Gynecol 1996;174:1433-40.
35. Yoon BH, Romero R, Park JS, et al. Fetal exposure to an intra-amniotic inflammation and the development of cerebral palsy at the age of three years. Am J Obstet Gynecol 2000;182:675-81.
36. Redline RW, Wilson-Costello D, Borawski E, et al. Placental lesions associated with neurologic impairment and cerebral palsy in very low-birth-weight infants. Arch Pathol Lab Med 1998; 122:1091-8.
37. Vigneswaren R. Infection and preterm birth: Evidence of a common causal relationship with bronchopulmonary dysplasia and cerebral palsy. J Paediatr Child Health 2000;36:293-6.
38. Watterberg KL, Demers LM, Scott SM, et al. Chorioamnionitis and early lung inflammation in infants whom bronchopulmonary dysplasia develops. Pediatrics 1996;97:210-5.
39. Yoon BH, Romero R, Kim KS, et al. A systemic fetal inflammatory response and the development of bronchopulmonary dysplasia. Am J Obstet Gynecol 1999;181:773-9.
40. Jobe AH, Ikegami M. Mechanisms initiating lung injury in the preterm. Early Hum Dev 1998; 53:81-94.
41. Nelson KB, Dambrosia JM, Grether JK. Neonatal cytokines and coagulation factors in children with cerebral palsy. Ann Neurol 1998;44:665-75.
42. Gaudet LM, Smith GN. Cerebral palsy and chorioamnionitis: The inflammatory cytokine link. Obstet Gynecol Surv 2001;56:433-6.
43. Grether JK, Nelson KB. Maternal infection and cerebral palsy in infants of normal birth weight. JAMA 1997;278:207-11.
44. Wu YW, Colford Jr JM. Chorioamnionitis as a risk factor for cerebral palsy: A meta-analysis. JAMA 2000;284:1417-24.
45. Thorp Jr JM, Hartmann KE, Berkman ND, et al. Antibiotic therapy for the treatment of preterm labor: a review of the evidence. Am J Obstet Gynecol 2002;186:587-92.
46. King J, Flenady V. Antibiotics for preterm labour with intact membranes. Cochrane Pregnancy and Childbirth Group. Cochrane Database of Systematic Reviews 2002;(2):CD002255 (PMID 12076443).
47. Kenyon SL, Taylor DJ, Tarnow-Mordi W. Broad-spectrum antibiotics for spontaneous preterm labour: the ORACLE II randomised trial. ORACLE Collaborative Group. Lancet 2001;357: 989-94.
48. Ehrenberg HM, Mercer BM. Antibiotics and the management of preterm premature rupture of the fetal membranes. Clin Perinatol 2001;28:807-18.
49. Mercer BM, Miodovnik M, Thurnau GR, et al. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. A randomized controlled trial. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. JAMA 1997;278:989-95.
50. Kenyon S, Boulvain M, Neilson J. Antibiotics for preterm premature rupture of membranes. Cochrane Database Syst Rev 2001;(4):CD001058 (PMID 11687090).
51. Kenyon SL, Taylor DJ, Tamow-Mordi W. Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: The ORACLE I randomised trial. ORACLE Collaborative Group. Lancet 2001;357:979-88.
52. Arias F, Victoria A, Cho K, et al. Placental histopathology and clinical characteristics of patients with preterm premature rupture of membranes. Obstet Gynecol 1997;89:265-71.
53. Mercer BM, Crocker LG, Boe NM, et al. Induction versus expectant management in premature rupture of the membranes with mature amniotic fluid at 32 to 36 weeks: A randomized trial. Am J Obstet Gynecol 1993;169:775-82.
54. Cox SM, Leveno KJ. Intentional delivery versus expectant management with preterm ruptured membranes at 30-34 weeks' gestation. Obstet Gynecol 1995;86:875-9.
55. Naef RW, Allbert JR, Ross EL, et al. Premature rupture of membranes at 34 to 37 weeks' gestation: Aggressive versus conservative management. Am J Obstet Gynecol 1998;178: 126-30.
56. Mittendorf R, Pryde PG. An overview of the possible relationship between antenatal pharmacologic magnesium and cerebral palsy. J Perinat Med 2000;28:286-93.
57. Hirtz DG, Nelson K. Magnesium sulfate and cerebral palsy in premature infants. Curr Opin Pediatr 1998;10:131-7.
58. Nelson KB, Grether JK. Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants? Pediatrics 1995;95:263-9.
59. Schendel DE, Berg CJ, Yeargin-Allsopp M, et al. Prenatal magnesium sulfate exposure and the risk of cerebral palsy on mental retardation among very-low-birthweight children aged 3 to 5 years. JAMA 1996;276:1805-10.
60. Grether JK, Hoogstrate J, Selvin S, et al. Magnesium sulfate tocolysis and risk of neonatal death. Am J Obstet Gynecol 1998;178:1-6.
61. Grether JK, Hoogstrate J, Walsh-Greene E, et al. Magnesium sulfate tocolysis and risk of spastic cerebral palsy in premature children born to women without preeclampsia. Am J Obstet Gynecol 2000;183:717-25.
62. Boyle CA, Yeargin-Allsopp M, Schendel DE, et al. Tocolytic magnesium sulfate exposure and risk of cerebral palsy among children with birth weights less than 1,750 grams. Am J Epidemiol 2000;152:120-4.
63. Mittendorf R, Covert R, Boman J, et al. Is tocolytic magnesium sulphate associated with increased total paediatric mortality? Lancet 1997;350:1517-8.
64. Mittendorf R, Bentz L, Borg M, et al. Does exposure to antenatal magnesium sulfate prevent cerebral palsy? Am J Obstet Gynecol 2000;182:S20.
65. Herlenius E, Lagercrantz H. Neurotransmitters and neuromodulators during early human development. Early Hum Dev 2001;65:21-37.
66. Liggins GC. Premature delivery of foetal lambs infused with glucocorticoids. J Endocrinol 1969; 45:515-23.
67. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 1972;50:515-25.
68. Crowley PA. Antenatal corticosteroid therapy: A meta-analysis of the randomized trials, 1972 to 1994. Am J Obstet Gynecol 1995;173:322-35.
69. NIH Consensus Development Panel on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes. Effect of corticosteroids for fetal maturation on perinatal outcomes. JAMA 1995;273:413-8.
70. Thorp JA, Jones PG, Knox E, et al. Does antenatal corticosteroid therapy affect birth weight and head circumference? Obstet Gynecol 2002;99(1):101-8.
71. MacArthur BA, Howie RN, Dezoete JA, et al. School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics 1982;70:99.
72. Schmand B, Neuvel J, Smolders-de Haas H, et al. Psychological development of children who were treated antenatally with corticosteroid to prevent respiratory distress syndrome. Pediatrics 1990;86:58-64.
73. Smolders-de Haas H, Neuvel J, Schmand B, et al. Physical development and medical history of children who were treated antenatally with corticosteroids to prevent RDS. Pediatrics 1990; 86:65-70.
74. Aghajafari F, Murphy K, Matthews S, et al. Repeated doses of antenatal corticosteroids in animals: a systematic review. Am J Obstet Gynecol 2002;186:843-9.
75. Guinn DA, Atkinson MW, Sullivan L, et al. Single vs weekly courses of antenatal corticosteroids for women at risk of preterm delivery: A randomized controlled trial. JAMA 2001;286: 1581-7.
76. NIH Consensus Statement. Antenatal Corticosteroids Revisited: Repeat Courses. 2000;17(2):1-10.
77. Schellenberg JC, Liggins GC, Manzai M, et al. Synergistic hormonal effects on lung maturation in fetal sheep. J Appl Physiol 1988;65:94-100.
78. Knight DB, Liggins GC, Wealthall SR. A randomized, controlled trial of antepartum thyrotropin-releasing hormone and betamethasone in the prevention of respiratory disease in preterm infants. Am J Obstet Gynecol 1994;171:11-6.
79. Morales WJ, O'Brien WF, Angel JL, et al. Fetal lung maturation: The combined use of corticosteroids and thyrotropin-releasing hormone. Obstet Gynecol 1989;73:111-6.
80. Crowther CA, Alfirevic Z, Haslam RR. Prenatal thyrotropin-releasing hormone for preterm birth. Cochrane Database of Systematic Reviews 2002;(2):CD000019.
81. Ballard RA, Ballard PL, Creasy RK, et al. Respiratory disease in very-low-birthweight infants after prenatal thyrotropin-releasing hormone and glucocorticoid. TRH Study Group. Lancet 1992;339:510-5.
82. Ballard RA, Ballard PL, Cnaan A, et al. Antenatal thyrotropin-releasing hormone to prevent lung disease in preterm infants. North American Thyrotropin-Releasing Hormone Study Group. N Engl J Med 1998;338:493-8.
83. Crowther CA, Hiller JE, Haslam RR, et al. Australian Collaborative Trial of Antenatal Thyrotropin-Releasing Hormone: Adverse effects at 12-month follow-up. ACTOBAT Study Group. Pediatrics 1997;99:311-7.
84. Thorp JA, Gaston L, Caspers DR, et al. Current concepts and controversies in the use of vitamin K. Drugs 1995;49:376-87.
85. Thorp JA, Parriott J, Ferrette-Smith D, et al. Antepartum vitamin K and phenobarbital for preventing intraventricular hemorrhage in the premature newborn: A randomized, double-blind, placebo-controlled trial. Obstet Gynecol 1994;83:70-6.
86. De Carolis S, De Carolis MP, Caruso A, et al. Antenatal phenobarbital in preventing intraventricular hemorrhage in premature newborns. Fetal Ther 1988;3:224-9.
87. Morales WJ. Antenatal therapy to minimize neonatal intraventricular hemorrhage. Clin Obstet Gynecol 1991;34:328-35.
88. Chen HJ, Roloff DW. Routine administration of phenobarbital for the prevention of intraventricular hemorrhage in premature infants: five years' experience. J Perinatol 1994;14:15-22.
89. Thorp JA, Ferrette-Smith D, Gaston LA, et al. Combined antenatal vitamin K and phenobarbital therapy for preventing intracranial hemorrhage in newborns less than 34 weeks' gestation. Am J Obstet Gynecol 1995;86:1-8.
90. Shankaran S, Papile LA, Wright LL, et al. The effect of antenatal phenobarbital therapy on neonatal intracranial hemorrhage in preterm infants. N Engl J Med 1997;337:466-71.
91. Thorp JA, O'Connor M, Jones AM, et al. Does perinatal phenobarbital exposure affect developmental outcome at age 2? Am J Perinatol 1999;16:51-60.
92. Shankaran S, Woldt E, Nelson J, et al. Antenatal phenobarbital therapy and neonatal outcome. II: Neurodevelopmental outcome at 36 months. Pediatrics 1996;97:649-52.